Schilder, R.J., Sill, M.W., Lee, R.B., et al. (2008) Phase II Evaluation of Imatinib Mesylate in the Treatment of Recurrent or Persistent Epithelial Ovarian or Primary Peritoneal Carcinoma: A Gynecologic Oncology Group Study. Journal of Clinical Oncology, 26, 3418-3425.
https://doi.org/10.1200/JCO.2007.14.3420

has been cited by the following article:

• TITLE: Research Progress of c-Kit in Platinum-Resistant Ovarian Cancer

  AUTHORS: Shiwei Li, Xiaolan Ke, Ning Hu, Xiaowen Wang

  KEYWORDS: Ovarian Cancer, Platinum Resistance, c-Kit

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.13 No.2, February 25, 2025

  ABSTRACT: c-Kit (CD117) is a type IIIa receptor tyrosine kinase (RTK) that plays a key role in regulating the normal physiological processes of cells. In addition, the activation of c-Kit activates the tyrosine kinase signal transduction pathway, which is closely related to the occurrence and development of gynecological tumors, especially ovarian cancer. This article reviews the mechanisms of platinum resistance in ovarian cancer and the research progress of c-Kit in ovarian cancer.